Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: A Children's Oncology Group study

Abstract

Background A Phase II trial was developed to determine the efficacy and toxicity of intravenous vinorelbine, a semi‐synthetic vinca alkaloid, in children, adolescent, and young adults with recurrent or refractory solid malignancies. Procedures Fifty patients were enrolled among three strata: soft tissue sarcomas [rhabdomyosarcoma (RMS), non‐rhabdomyosarcoma, primitive neuroepithelial tumor] (20 patients); brain tumors [astrocytoma (4 patients), medulloblastoma (2 patients), other (16 patients)] (22 patients); neuroblastoma (8 patients). Vinorelbine was given weekly for 6 consecutive weeks during an 8‐week interval. The response rate and toxicity profile was assessed. Results Among the first 35 patients treated at 33.75 mg/m²/dose, 25 experienced grades 3–4 neutropenia (75%). The dose was decreased to 30 mg/m²/dose in the remaining 15 patients. The median age was 10 years (range, 1–25). Four responses (one complete, three partial) occurred within the soft tissue sarcoma strata (all with RMS) and two occurred in the brain tumor group (medulloblastoma and astrocytoma). The most common toxicities were hematological and neurological. Conclusion Vinorelbine at dose of 30 mg/m² can be safely administered to children with recurrent or refractory solid malignancies. The study design identified vinorelbine to be active in the sarcoma category, with a response rate of 36% (4/11) among RMS patients. Pediatr Blood Cancer 2009;53:590–593.